Analytical Data
-
Gene name
KIAA1430
- Application
-
Alternative Names
CFAP97; KIAA1430Cilia- and flagella-associated protein 97
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9P2B7
-
Expression Region
1-453aa
-
AA Sequence
MDQFGDILEGEVDHSFFDSDFEEGKKCETNSVFDKQNDDPKERIDKDTKNVNSNTGMQTTENYLTEKGNERNVKFPPEHPVENDVTQTVSSFSLPASSRSKKLCDVTTGLKIHVSIPNRIPKIVKEGEDDYYTDGEESSDDGKKYHVKSKSAKPSTNVKKSIRKKYCKVSSSSSSSLSSSSSGSGTDCLDAGSDSHLSDSSPSSKSSKKHVSGITLLSPKHKYKSGIKSTETQPSSTAPKCGHYPEESEDTVTDVSPLSTPDISPLQSFELGIANDQKVKIKKQENVSQEIYEDVEDLKNNSKYLKAAKKGKEKHEPDVSSKSSSVLDSSLDHRHKQKVLHDTMDLNHLLKAFLQLDKKGPQKHHFDQPSVAPGKNYSFTREEVRQIDRENQRLLKELSRQAEKPGSKSTIPRSADHPPKLYHSALNRQKEQQRIERENLTISLCHPGWSAVT
-
Molecular Weight
49.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIAA1430, also known as KIAA1430 or C3orf16, has gained attention in recent years due to its potential role in various biological processes and diseases. Initially identified as a gene of unknown function, studies have gradually revealed its involvement in RNA metabolism and regulation, particularly in the context of mRNA splicing and stability. Researchers have discovered that KIAA1430 interacts with key components of the RNA processing machinery, suggesting a significant contribution to post-transcriptional gene expression regulation. Furthermore, emerging evidence suggests that KIAA1430 may play a role in cancer biology, as altered expression levels have been observed in various tumors. This prompted further investigation into its potential as a biomarker and therapeutic target. Additionally, the protein is implicated in immune responses, and its dysregulation may contribute to autoimmune disorders. As the understanding of KIAA1430's functions continues to evolve, ongoing research aims to elucidate the precise molecular mechanisms by which this protein influences cellular processes, thereby providing insights into its potential applications in disease diagnosis and treatment. Overall, the study of KIAA1430 offers a promising avenue for enhancing our understanding of gene regulation and developing novel therapeutic strategies for relevant diseases.
